Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Cash from Financing Activities (2016 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Cash from Financing Activities for 15 consecutive years, with -$25.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities fell 677.04% year-over-year to -$25.6 million, compared with a TTM value of -$17.0 million through Dec 2025, down 112.08%, and an annual FY2025 reading of -$17.0 million, down 112.08% over the prior year.
  • Cash from Financing Activities was -$25.6 million for Q4 2025 at Catalyst Pharmaceuticals, down from $4.7 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $141.0 million in Q1 2024 and bottomed at -$25.6 million in Q4 2025.
  • Average Cash from Financing Activities over 5 years is $5.3 million, with a median of -$32500.0 recorded in 2023.
  • The sharpest move saw Cash from Financing Activities crashed 10397.22% in 2021, then soared 94563.76% in 2024.
  • Year by year, Cash from Financing Activities stood at -$2.5 million in 2021, then surged by 189.19% to $2.3 million in 2022, then crashed by 129.52% to -$665000.0 in 2023, then soared by 766.62% to $4.4 million in 2024, then plummeted by 677.04% to -$25.6 million in 2025.
  • Business Quant data shows Cash from Financing Activities for CPRX at -$25.6 million in Q4 2025, $4.7 million in Q3 2025, and $872000.0 in Q2 2025.